NCT02442258 - Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Renal Impairment

Interventions

DRUG

ABT-493

A single dose of ABT-493 will be given orally in combination with ABT-530.

DRUG

ABT-530

A single dose of ABT-530 will be given orally in combination with ABT-493.

Trial Locations (3)

Site Reference ID/Investigator# 137332, Grafton, Auckland

Site Reference ID/Investigator# 132889, Orlando

Site Reference ID/Investigator# 132890, Miami